RT info:eu-repo/semantics/article
T1 An Overview of Endometriosis and Potential Pharmacogenetic Targets
A1 Pérez Gómez, Noelia
A1 Martínez-Zamora, María Ángeles
A1 Carmona, Francisco
A1 Novalbos, Jesús
A1 Abad-Santos, Francisco
A1 Koller, Dora
A1 Saiz Rodríguez, Miriam
K1 Drug response
K1 Endometriosis
K1 Pharmacogenetics
K1 Precision medicine
K1 Endometriosis
AB Endometriosis is a chronic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. It affects approximately 10–15% of women of reproductive age globally and is characterized by heterogeneous symptoms with chronic pelvic pain, dysmenorrhea, and infertility being the most common. Although pharmacological treatments are available to manage its symptoms, many women either do not respond to these therapies or experience adverse drug reactions (ADRs) that outweigh the original symptoms of endometriosis. Current research highlights a critical gap in pharmacogenetic biomarkers for endometriosis treatment, limiting the potential for personalized therapeutic strategies. Integrative multi-omics approaches combining genetic, inflammatory, and hormonal profiles may enhance patient stratification and optimize individualized care.
PB Springer
SN 0724-8741
YR 2026
FD 2026-03
LK https://hdl.handle.net/10259/11620
UL https://hdl.handle.net/10259/11620
LA eng
NO Open access funding provided by FEDER European Funds and the Junta de Castilla y León under the Research and Innovation Strategy for Smart Specialization (RIS3) of Castilla y León 2021-2027. The authors acknowledge support from “Fundació de la Marató” (project PI049956). D.K.is supported by a ‘Ramón y Cajal’ fellowship from the Spanish Ministry of Science and Innovation (RYC2024-050099-I). The contract of N.P.G. was funded by the predoctoral research personnel hiring program, co-funded by the European Social Fund Plus (ESF +) of the Ministry of Education of the Regional Government of Castilla y León (BU-103–25).
DS Repositorio Institucional de la Universidad de Burgos
RD 14-may-2026